Global Agitation in Delirium Management Market to Surpass US$ 285.4 Million by 2027, Says Coherent Market Insights (CMI)

Global Agitation in Delirium Management Market to Surpass US$ 285.4 Million by 2027, Says Coherent Market Insights (CMI)




Global Agitation in Delirium Management Market to Surpass US$ 285.4 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#Agitation–According to Coherent Market Insights, the global agitation in delirium management market is estimated to be valued at US$ 212.7 million in 2020 and is expected to exhibit a CAGR of 4.3% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Agitation in Delirium Management Market:

Key trends in the market include increasing research and development activities, product launches and approvals, manufacturing facility expansion, and others.

Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients. For instance, in 2020, BioXcel Therapeutics Inc was conducting clinical trials for examining the safety, efficacy, tolerability, and for calculating the minimum dose of administration of dexmedetomidine sublingual film for the treatment of hyperactive delirium (i.e., delirium with agitation) in the intensive care unit (ICU) setting. The study is in Phase II of the clinical trial and is expected to be completed in June 2021.

Increasing product approvals by the regulatory authorities is expected to drive the growth of the market over the forecast period. For instance, on December 9, 2020, Aurobindo Pharma received approval from the U.S. FDA to manufacture and market Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 g/50 mL and 400 g/100 mL single dose flexible containers.

Request for Sample copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/4430

The increasing prevalence of delirium in ICU patients is expected to aid in growth of the hospital pharmacies segment over the forecast period. For instance, according to the National Center for Biotechnology Information: 2018 report, globally, the prevalence of delirium in ICU was reported to be 32.3%. In the specialized ICU, the prevalence of delirium was approximately 77% in ventilated burn patients. According to the same source, the incidence of delirium in the ICU ranged from 45% to 87%.

Key Market Takeaways:

Increasing facility expansion by the market players is expected to drive the growth of the global agitation in delirium management market over the forecast period. For instance, in 2019, Fresenius Kabi AG expanded its pharmaceutical manufacturing facility in Wilson, Ohio, U.S. The new manufacturing site would increase the production of affordable generic medicines that are used in the hospitals and clinics. The manufacturing facility will also increase the production of drugs required for agitation in delirium.

Among regions, North America is expected to hold a dominant position in the global agitation in delirium management market over the forecast period, owing to increasing launches of drugs for the treatment of agitation in delirium in this region. For instance, on September 25, 2020, Dr Reddy’s Laboratories launched Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection form, indicated for sedation of initially intubated and mechanically ventilated patients during treatment of hyperactive delirium (agitation in delirium) in an intensive care setting. It is a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection form approved by the U.S. Food and Drug Administration (USFDA).

Competitive Landscape:

Key players operating in the global agitation in delirium management market include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis International AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., and BioXcel Therapeutics, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4430

Market Segmentation:

  • Global Agitation in Delirium Management Market, By Drug:

    • First-generation Antipsychotics
    • Second-generation Antipsychotics
    • Benzodiazepines
    • Others
  • Global Agitation in Delirium Management Market, By Route of Administration:

    • Oral
    • Intramuscular
    • Others
  • Global Agitation in Delirium Management Market, By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Agitation in Delirium Management Market, By Region:

    • North America

      • U.S.
      • Canada
    • Latin America

      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe

      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
    • Asia Pacific

      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
    • Middle East

      • GCC
      • Israel
      • Rest of Middle East
    • Africa

      • South Africa
      • Central Africa
      • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter